NCT04778202 is a clinical trial of blood sample collection in Breast Cancer, sponsored by Assiut University.

Who is sponsoring NCT04778202?

NCT04778202 is sponsored by Assiut University.

What drugs are being tested in NCT04778202?

Interventions in NCT04778202: blood sample collection.

What condition does NCT04778202 study?

NCT04778202 studies Breast Cancer.

Is NCT04778202 still recruiting?

NCT04778202 is currently status unknown. Last updated 8 March 2021.

Last reviewed 2021-03-08 · How we verify

NCT04778202

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Diagnostic and Prognostic Value of MicroRNA in Breast Cancer Patients

Status unknown Last updated 8 March 2021

What this trial tests

trial testing blood sample collection in Breast Cancer in 50 participants. Status unknown.

Timeline

1 March 2022

Primary endpoint
1 March 2023

1 March 2024

Quick facts

Lead sponsor	Assiut University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	50
Start date	1 March 2022
Primary completion	1 March 2023
Estimated completion	1 March 2024

Drugs / interventions tested

blood sample collection — full drug profile →

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Assiut University

Who can join

Adults 18 to 70, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to evaluate the role of miRNA 125a -5p and miRNA143-3p as a non invasive biomarker in diagnosis of breast cancer and the relationship between MiRNA expression and histopathological features as tumor stage ,grade ,molecular subtypes. Also trying to correlate the results with MRI radiological findings which may help in better selection of treatment protocols.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Breast cancer tumor microenvironment affects Treg/IL-17-producing Treg/Th17 cell axis: Molecular and therapeutic perspectives.
Seif F, Torki Z, Zalpoor H, Habibi M, et al · · 2023 · cited 31× · PMID 36816749 · DOI 10.1016/j.omto.2023.01.001
miR-125 in Breast Cancer Etiopathogenesis: An Emerging Role as a Biomarker in Differential Diagnosis, Regenerative Medicine, and the Challenges of Personalized Medicine.
Piergentili R, Marinelli E, Cucinella G, Lopez A, et al · · 2024 · cited 12× · PMID 38525735 · DOI 10.3390/ncrna10020016
Non-Coding RNAs in Breast Cancer: Diagnostic and Therapeutic Implications.
Beňačka R, Szabóová D, Guľašová Z, Hertelyová Z. · · 2024 · cited 7× · PMID 39795985 · DOI 10.3390/ijms26010127
Unraveling the Potential of miRNAs from CSCs as an Emerging Clinical Tool for Breast Cancer Diagnosis and Prognosis.
Nogueras Pérez R, Heredia-Nicolás N, de Lara-Peña L, López de Andrés J, et al · · 2023 · cited 5× · PMID 37958993 · DOI 10.3390/ijms242116010

Verify or expand the search:

Other trials of blood sample collection

Trials testing the same drug.

NCT07499739 — Mpox Biology, Outcome, Transmission and Epidemiology - Tracking the Immune Response After mpoX vaCcination (MBOTE-TRAXX) · Phase 4 · not yet recruiting
NCT06103357 — Identification of Biomarkers in Subjects With Coronary Syndrome (PLAQUE Study) · unknown
NCT07261761 — Cytokines as Diagnostic Markers of Pulpal Inflammation and Their Impact on the Outcome of Vital Pulp Therapy · NA · completed
NCT05515081 — Antibody Response and Longevity Post SARS-CoV-2 Vaccine (SARS-AB) · NA · completed
NCT04793061 — Circulating Tumor DNA as Marker for Response to Antineoplastic Treatment of Metastatic Cancer (FLUIDO) · unknown

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04778202 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 8 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04778202.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing